AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31833543 — intervention group
Group type: EXPERIMENTAL
Intervention: IVCS + Antibiotics (amoxicillin, vancomycin, metronidazole, doxycycline/ciprofloxacin)
Number of subjects: 28
Study 31833543 — intervention group
Group type: COMPARATOR
Intervention: IVCS only
Number of subjects: 28
Study 31833543 — intervention group
Group type: EXPERIMENTAL
Intervention: IVCS + Antibiotics
Number of subjects: 28
Study 30797222 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (25, 50, 75 or 150 μg, single dose)
Number of subjects: 20
Study 30797222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28492920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous 0.5-mg ranibizumab therapy
Number of subjects: 305
Study 28492920 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 305
Study 25929985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse assisted online cognitive‐behavioral self‐management intervention (DESTRESS‐PC)
Number of subjects: 80
Study 25929985 — intervention group
Group type: COMPARATOR
Intervention: Optimized usual primary care PTSD Treatment (OUC)
Number of subjects: 80
Study 23282858 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT+ arm
Number of subjects: 165
Study 23282858 — intervention group
Group type: COMPARATOR
Intervention: no CAT arm
Number of subjects: 165
Study 21167682 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight fast
Number of subjects: 39
Study 21167682 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich snack in the evening
Number of subjects: 39
Study 18976267 — intervention group
Group type: EXPERIMENTAL
Intervention: KaVo Everest HPC crowns
Number of subjects: 224
Study 18976267 — intervention group
Group type: COMPARATOR
Intervention: Gold crowns
Number of subjects: 224
Study 17304146 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited sampling strategy using two concentration measurements (0.5 and 6 hours or 0.5 and 8 hours after the end of infusion)
Number of subjects: 51
Study 17304146 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic parameters
Number of subjects: 51
Study 17304146 — intervention group
Group type: COMPARATOR
Intervention: Traditional method using five‐ to nine‐concentration data
Number of subjects: 51
Study 12960682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) at 0.5 microg/kg/min
Number of subjects: 30
Study 12960682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10756495 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance program (group 2)
Number of subjects: 149
Study 10756495 — intervention group
Group type: EXPERIMENTAL
Intervention: Incarcerated women (group 1)
Number of subjects: 149
Study 10756495 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 149
Study 10756495 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 149
Study 10756495 — intervention group
Group type: EXPERIMENTAL
Intervention: Incarcerated women (group 1) and methadone maintenance group (group 2)
Number of subjects: 149
Study 8789548 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk perfusion (10 mL at 3 mL/min) in patients with cow's milk intolerance
Number of subjects: 13
Study 8789548 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 13
Study 1362031 — intervention group
Group type: EXPERIMENTAL
Intervention: CLF vaccine (720 ELISA units)
Number of subjects: 0
Study 1362031 — intervention group
Group type: EXPERIMENTAL
Intervention: HM175 vaccine (1440 ELISA units, double dose)
Number of subjects: 0
Study 1362031 — intervention group
Group type: EXPERIMENTAL
Intervention: HM175 vaccine (single dose at months 0 and 1)
Number of subjects: 0
Study 1362031 — intervention group
Group type: EXPERIMENTAL
Intervention: HM175 vaccine (third dose)
Number of subjects: 0
Study 6528959 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur, 300 mg twice daily
Number of subjects: 8
Study 6528959 — intervention group
Group type: COMPARATOR
Intervention: Uniphylline, 600 mg once daily
Number of subjects: 8
Study 6528959 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur and Uniphylline
Number of subjects: 8
Study 3453158 — intervention group
Group type: EXPERIMENTAL
Intervention: stepped‐up outreach rehabilitation program
Number of subjects: 57
Study 3453158 — intervention group
Group type: COMPARATOR
Intervention: usual treatment
Number of subjects: 57
Study 28278612 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary public service announcement after an organ donation story
Number of subjects: 310
Study 28278612 — intervention group
Group type: COMPARATOR
Intervention: Viewing the same episode of the program on its own
Number of subjects: 310
Study 27026689 — intervention group
Group type: EXPERIMENTAL
Intervention: Total power Doppler joint count ≤1 during a combined DAS28-ESR/MSUS assessment
Number of subjects: 111
Study 27026689 — intervention group
Group type: COMPARATOR
Intervention: DAS28-erythrocyte sedimentation rate (ESR) <3.2
Number of subjects: 111
Study 27026689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive DMARD therapy
Number of subjects: 111
Study 27026689 — intervention group
Group type: COMPARATOR
Intervention: Standard DMARD therapy
Number of subjects: 111
Study 23999998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral cholecalciferol supplementation (140,000 IU/month)
Number of subjects: 60
Study 23999998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22882767 — intervention group
Group type: EXPERIMENTAL
Intervention: Single purse string with four-point traction (G2)
Number of subjects: 60
Study 22882767 — intervention group
Group type: COMPARATOR
Intervention: Single purse string with two-point traction (G1)
Number of subjects: 60
Study 18719048 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTP/CBD/ granisetron
Number of subjects: 12
Study 18719048 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTP/CBD/domperidone
Number of subjects: 12
Study 18719048 — intervention group
Group type: COMPARATOR
Intervention: 5-HTP/CBD/placebo
Number of subjects: 12
Study 18448569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg (q.d.)
Number of subjects: 35
Study 18448569 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine 600 mg (b.i.d.)
Number of subjects: 35
Study 18448569 — intervention group
Group type: COMPARATOR
Intervention: Pactimibe sulfate without ketoconazole or quinidine
Number of subjects: 35
Study 15989987 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐FSH and LH (hMG 75 IU FSH + 75 IU LH activity daily for four days with r‐FSH 150 IU/day)
Number of subjects: 46
Study 15989987 — intervention group
Group type: COMPARATOR
Intervention: r‐FSH (200 IU/day for the first four days)
Number of subjects: 46
Study 12698090 — intervention group
Group type: EXPERIMENTAL
Intervention: pp67 mRNA NASBA
Number of subjects: 82
Study 12698090 — intervention group
Group type: COMPARATOR
Intervention: Quantitative antigenemia
Number of subjects: 82
Study 11002232 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-CHOP (radiotherapy followed by six cycles of CHOP chemotherapy)
Number of subjects: 53
Study 11002232 — intervention group
Group type: COMPARATOR
Intervention: RT (radiotherapy alone)
Number of subjects: 53
Study 8623886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 200 mg
Number of subjects: 10
Study 8623886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg
Number of subjects: 10
Study 8623886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (200 mg and 400 mg)
Number of subjects: 10
Study 8623886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1729457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A (60,000 micrograms retinol equivalent)
Number of subjects: 236
Study 1729457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 6146341 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 12
Study 6146341 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 6146341 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 12
Study 6146341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31593830 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched molecularly targeted agents (MTAs) classified into ESCAT tiers II, IIIA, IIIB, and IVA
Number of subjects: 153
Study 29855249 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing rods surgery for severe EOS
Number of subjects: 107
Study 29855249 — intervention group
Group type: COMPARATOR
Intervention: Growing rods surgery for moderate EOS
Number of subjects: 107
Study 27735021 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil 60 mg and α-lipoic acid 600 mg in 250 mL normal saline, intravenous drip once per day for 2 weeks
Number of subjects: 76
Study 27735021 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 5 mg orally, once per night for 2 weeks
Number of subjects: 76
Study 27735021 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil combined with α-lipoic acid
Number of subjects: 76
Study 27735021 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 76
Study 24263619 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 0.4 U/kg via subcutaneous injection once-daily for six days
Number of subjects: 0
Study 24263619 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 0
Study 22908112 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent/Adol
Number of subjects: 0
Study 22908112 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Only
Number of subjects: 0
Study 22908112 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 20521272 — intervention group
Group type: EXPERIMENTAL
Intervention: GTFT 2.0 g/L
Number of subjects: 15
Study 20521272 — intervention group
Group type: EXPERIMENTAL
Intervention: GTFT 1.8 g/L
Number of subjects: 15
Study 20521272 — intervention group
Group type: EXPERIMENTAL
Intervention: GTFT 1.6 g/L
Number of subjects: 15
Study 20521272 — intervention group
Group type: EXPERIMENTAL
Intervention: GTFT 1.4 g/L
Number of subjects: 15
Study 18478132 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy (CE) in patients with PHT
Number of subjects: 35
Study 18478132 — intervention group
Group type: COMPARATOR
Intervention: Capsule endoscopy (CE) in controls (no PHT)
Number of subjects: 35
Study 18478132 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PHE in patients with PHT
Number of subjects: 35
Study 18478132 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SB varices in patients with PHT
Number of subjects: 35
Study 16186600 — intervention group
Group type: EXPERIMENTAL
Intervention: iodine‐131 tositumomab
Number of subjects: 250
Study 12857652 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing information about the severity of treatment and illness consequences
Number of subjects: 119
Study 12857652 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing information about colorectal cancer risks
Number of subjects: 119
Study 12857652 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 119
Study 10774083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent and continuous malaria chemoprophylaxis using chloroquine and proguanil
Number of subjects: 701
Study 10774083 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 701
Study 9001836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (6.25, 12.5, 25, 50, or 100 mg/d)
Number of subjects: 45
Study 9001836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9001836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 45
Study 1291697 — intervention group
Group type: EXPERIMENTAL
Intervention: Group behavioral therapy
Number of subjects: 0
Study 1291697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral marital treatments
Number of subjects: 0
Study 1291697 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 2951089 — intervention group
Group type: EXPERIMENTAL
Intervention: Human ultralente insulin (6 U)
Number of subjects: 8
Study 2951089 — intervention group
Group type: COMPARATOR
Intervention: Bovine ultralente insulin (6 U)
Number of subjects: 8
Study 2951089 — intervention group
Group type: EXPERIMENTAL
Intervention: Human ultralente insulin (24 U)
Number of subjects: 8
Study 2951089 — intervention group
Group type: COMPARATOR
Intervention: Bovine ultralente insulin (24 U)
Number of subjects: 8
Study 2951089 — intervention group
Group type: COMPARATOR
Intervention: Bovine ultralente insulin
Number of subjects: 8
Study 2951089 — intervention group
Group type: EXPERIMENTAL
Intervention: Human ultralente insulin
Number of subjects: 8
Study 30726261 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky substance use mentioned in C&P examination
Number of subjects: 208
Study 30726261 — intervention group
Group type: COMPARATOR
Intervention: No risky substance use mentioned in C&P examination
Number of subjects: 208
Study 30309276 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly health coaching
Number of subjects: 0
Study 30309276 — intervention group
Group type: COMPARATOR
Intervention: Monthly health coaching
Number of subjects: 0
Study 26766172 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed assortment of HPDs with or without information
Number of subjects: 491
Study 26766172 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web‐based information
Number of subjects: 491
Study 26766172 — intervention group
Group type: EXPERIMENTAL
Intervention: Static web‐based information
Number of subjects: 491
Study 26766172 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed assortment of HPDs
Number of subjects: 491
Study 26766172 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed and web‐based information groups
Number of subjects: 491
Study 26766172 — intervention group
Group type: COMPARATOR
Intervention: Other interventions (static web-based information, interactive web-based information without mailed HPDs)
Number of subjects: 491
Study 24933322 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention condition (listening to audio instructions to pay attention to food)
Number of subjects: 48
Study 24933322 — intervention group
Group type: COMPARATOR
Intervention: Control condition (listening to an audio book with neutral content)
Number of subjects: 48
Study 22024949 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month physical activity (PA) intervention including aerobic, strength, and flexibility exercises, with walking as the primary mode.
Number of subjects: 361
Study 22024949 — intervention group
Group type: COMPARATOR
Intervention: Successful aging intervention (control group).
Number of subjects: 361
Study 20485203 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD 400 microg twice daily for 1 month, then 200 microg twice daily for 5 months
Number of subjects: 136
Study 20485203 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD 100 microg twice daily
Number of subjects: 136
Study 20485203 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD as needed for 1 year
Number of subjects: 136
Study 20485203 — intervention group
Group type: COMPARATOR
Intervention: DSCG
Number of subjects: 136
Study 18377991 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNY (Healthy Families New York)
Number of subjects: 1173
Study 18377991 — intervention group
Group type: COMPARATOR
Intervention: Control group (information and referrals to other services)
Number of subjects: 1173
Study 15774210 — intervention group
Group type: EXPERIMENTAL
Intervention: PRFA
Number of subjects: 112
Study 15774210 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 112
Study 12404669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study 10369427 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg three times daily)
Number of subjects: 105
Study 7590814 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2 chimeric anti-TNF alpha antibody (1 mg/kg)
Number of subjects: 73
Study 7590814 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2 chimeric anti-TNF alpha antibody (10 mg/kg)
Number of subjects: 73
Study 7590814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1% human serum albumin)
Number of subjects: 73
Study 2351512 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric fever
Number of subjects: 100
Study 2351512 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute diarrhoeal diseases
Number of subjects: 100
Study 2351512 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctivitis
Number of subjects: 100
Study 2351512 — intervention group
Group type: EXPERIMENTAL
Intervention: Scabies
Number of subjects: 100
Study 2351512 — intervention group
Group type: EXPERIMENTAL
Intervention: Infective hepatitis
Number of subjects: 100
Study 367480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine with behaviour therapy
Number of subjects: 81
Study 367480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine without behaviour therapy
Number of subjects: 81
Study 367480 — intervention group
Group type: COMPARATOR
Intervention: Placebo with behaviour therapy
Number of subjects: 81
Study 367480 — intervention group
Group type: COMPARATOR
Intervention: Placebo without behaviour therapy
Number of subjects: 81
Study 30638416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab/ipilimumab combination therapy
Number of subjects: 0
Study 30638416 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 0
Study 30638416 — intervention group
Group type: COMPARATOR
Intervention: Markov model
Number of subjects: 0
Study 28796276 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (2.5 million IU)
Number of subjects: 16
Study 28796276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 26652335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining TKA
Number of subjects: 60
Study 26652335 — intervention group
Group type: COMPARATOR
Intervention: Posterior-stabilized TKA
Number of subjects: 60
Study 23146660 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3mg/kg)
Number of subjects: 30
Study 23146660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21546160 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine infusion (100-hour continuous intravenous infusion at 10-20mg/h)
Number of subjects: 6
Study 18505668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NSAIDs
Number of subjects: 585
Study 18505668 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical NSAIDs
Number of subjects: 585
Study 16826054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (10 MU/0.1 mL saline)
Number of subjects: 23
Study 12642540 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assessment and triage using a computerized decision support system by nurses or paramedics.
Number of subjects: 1246
Study 12642540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 1246
Study 12642540 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard procedures without computerized decision support system)
Number of subjects: 1246
Study 11101549 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 0
Study 11101549 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up for incomplete questionnaires
Number of subjects: 0
Study 11101549 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal questionnaires
Number of subjects: 0
Study 11101549 — intervention group
Group type: COMPARATOR
Intervention: Conventional imputation of missing data
Number of subjects: 0
Study 9067299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 10 mg/70 kg
Number of subjects: 16
Study 9067299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 2.5 to 10 mg/70 kg
Number of subjects: 16
Study 9067299 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg/70 kg
Number of subjects: 16
Study 8090437 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% water content lenses
Number of subjects: 26
Study 8090437 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% water content lenses
Number of subjects: 26
Study 2682012 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow rate of 2.0 L.min‐1.m‐2
Number of subjects: 24
Study 2682012 — intervention group
Group type: COMPARATOR
Intervention: Flow rate of 1.5 L.min‐1.m‐2
Number of subjects: 24
Study 2682012 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile or pulsatile perfusion
Number of subjects: 24
Study 2682012 — intervention group
Group type: COMPARATOR
Intervention: Attempted pH and alpha stat control
Number of subjects: 24
Study 2682012 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher flow rate
Number of subjects: 24
Study 2682012 — intervention group
Group type: COMPARATOR
Intervention: Lower flow rate
Number of subjects: 24
Study 2682012 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteration in arterial pH
Number of subjects: 24
Study 2682012 — intervention group
Group type: COMPARATOR
Intervention: Flow rate, flow character, or arterial pH
Number of subjects: 24
Study 2682012 — intervention group
Group type: EXPERIMENTAL
Intervention: During cardiopulmonary bypass
Number of subjects: 24
Study 796856 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation of crystalline substrates with an Hg vapor lamp
Number of subjects: 0
Study 796856 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-blind studies
Number of subjects: 0
Study 796856 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind studies
Number of subjects: 0
Study 31281044 — intervention group
Group type: EXPERIMENTAL
Intervention: Current and ex-smokers
Number of subjects: 1987
Study 30576842 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention to improve adherence to P2Y12 inhibitors
Number of subjects: 0
Study 29097640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (IPT‐SP) alone
Number of subjects: 270
Study 29097640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (IPT‐SP) and insecticide treated nets (ITN)
Number of subjects: 270